Merck closed the regular hours trading day down 6% and Schering-Plough lost more than 11%.
当天交易日中，默克公司的股价下跌6%而先灵葆雅的股价跌幅超过了11%。
After Merck acquired Schering-Plough Corp. in 2009, though, the trial "was canceled," she said.
默克收购先灵葆雅公司在2009年后，虽然审判“被取消了，”她说。
Since it purchased Schering-Plough, Merck has wanted to increase its sales in emerging markets from 18% to 25% by 2013.
默克制药（MRK）收购Schering-Plough（先灵葆雅），希望到2013年在新兴市场的由目前的18%上升至25%。
This year the pharmaceutical mega-deal has made a long-awaited return, with Pfizer bidding for Wyeth and Merck for Schering-Plough.
随着今年辉瑞收购惠氏以及默克收购先灵葆雅，期待已久的制药行业巨额交易回归了。
Schering-Plough closed at $17.63, and, at current values, this is $23.61 for Schering-Plough for a total of $41.1 billion for this deal.
Schering-Plough 收于 17.63 美元，此次交易的总金额为 411 亿美元，按照现值计算，也就是每股 Schering-Plough 股票 23.61 美元。
Merck closed the regular hours trading day down 6% and Schering-Plough lost more than 11%. After the bell on Monday, both companies announced financial reports.
当天交易日中，默克公司的股价下跌6%而先灵葆雅的股价跌幅超过了11%。在周一开市以后，两家公司都公布了他们的财务报表。
The research was funded by Pfizer Inc, known generically as tadalafil, and Levitra or vardenafil, sold by GlaxoSmithKline, Bayer ag and Schering-Plough, work in a similar way to Viagra.
这项研究是由辉瑞公司发起，分类上称为他达拉非、艾力达或伐地那非，主要由葛兰素史克公司，拜耳公司和先灵葆雅公司销售，工作方式与伟哥类似。
Dr Nissen, a leading cardiologist, is up in arms over the way Merck and Schering-Plough, two American pharmaceutical giants, have handled a clinical trial of Vytorin, a blockbuster anticholesterol
Nissen博士，这位美国知名的心脏病专家，激烈的反对两个美国大型制药公司默克和先灵葆雅对Vytorin（一种由这两家公司联合研制的重磅炸弹级别的抗胆固醇的处方药）的临床试验所采取的做法。
Dr Nissen, a leading cardiologist, is up in arms over the way Merck and Schering-Plough, two American pharmaceutical giants, have handled a clinical trial of Vytorin, a blockbuster anticholesterol
Nissen博士，这位美国知名的心脏病专家，激烈的反对两个美国大型制药公司默克和先灵葆雅对Vytorin（一种由这两家公司联合研制的重磅炸弹级别的抗胆固醇的处方药）的临床试验所采取的做法。
应用推荐